Editorial: integrity of the autonomic nervous system in psychiatric and neurological disorders

Editorial on the Research Topic
Integrity of the Autonomic Nervous System in Psychiatric and Neurological Disorders

The autonomic nervous system is an essential neural control network of the human body that maintains physiologic balance. It regulates function of vital systems such as the cardiovascular system, the gastrointestinal system, and the skin. Autonomic neuronal structures permeate and innervate the entire human organism, managing its autonomic functions largely independent from consciousness and thereby securing its survival. Professor Phillip Low, a pioneer of autonomic neurology, has once referred to the autonomic nervous system as the “ Cinderella of Medicine,” a field of science, which attracted distinct interest in the scientific community but was limited by a substantial lack of coherent knowledge ( 1 ). When Low and a handful of out-of-the-box-thinking scientists such as Sir Roger Bannister from London, a famous neurologist and record-breaking middle-distance athlete, as well as David Robertson from Nashville, a distinguished neurologist and space physiologist, first embarked on the endeavor to explore the autonomic nervous system in the 1960s and 1970s, they could probably not foresee the future impact of their research. Nowadays, their observations provide a basis for diagnosis and treatment of highly prevalent and debilitating disorders, including metabolic disorders such as diabetes and neurodegenerative disorders such as Parkinson’s disease.

Over the past decades, techniques to assess structural and functional integrity of the autonomic nervous system have become paramount in understanding the pathophysiology of these diseases ( 2 – 4 ). Functional integrity of the sudomotor and cardiovascular autonomic nervous system can be tested non-invasively using well-established techniques such as quantitative sudomotor axon-reflex test, heart rate variability assessment and tilt table test ( 5 ). Structural integrity of the autonomic nervous system can be assessed using imaging of autonomic cerebral control centers such as the insular cortex as well as by immunohistochemical analysis of small nerve fibers in cutaneous punch biopsies ( 6 , 7 ). Designing and further advancing these techniques helped improving our pathophysiological understanding of autonomic nervous system disorders and allowed identification of novel diagnostic and therapeutic targets. For example, Parkinson’s disease has long been believed to be a primarily central synucleinopathy that affects brain regions of motor control. However, recent research has provided evidence that the peripheral autonomic nervous system is affected by deposition of misfolded alpha-synuclein long before motor control is clinically impaired. In these premotor disease stages the pathological form of alpha-synuclein can be detected in peripheral small autonomic nerve fibers of the skin, introducing a potential target for immunotherapy and other forms of targeted diagnostic and therapeutic approaches ( 8 – 10 ). As part of this article collection, Hong et al. reported an increased risk for atrial fibrillation in Parkinson’s disease highlighting the significance of cardiac dysautonomia in these patients. In this population-based study in 15, 434 newly diagnosed patients with Parkinson’s disease, the authors observed a significant predictive association between atrial fibrillation and Parkinson’s disease in premotor and early but not in later disease stages. This observation highlights the potential diagnostic value of atrial fibrillation in prodromal and early Parkinson’s disease as well as the potential impact of cardiac dysautonomia on cardiovascular risk in these patients.

While neurodegenerative synucleinopathies have recently been in the spotlight of autonomic neuroscience, autonomic dysfunction can in fact occur in a variety of neurological disorders such as diabetic or amyloidosis-related neuropathies, acute ischemic stroke, multiple sclerosis, neuroinflammatory diseases as well as psychiatric disorders such as anxiety and depression. This is of high clinical relevance as autonomic dysfunction can reduce quality of life, increase mortality, and increase cardiovascular risk. For example, autonomic impairment has been shown to independently increase mortality in patients with diabetic autonomic neuropathy and increase risk for cardiovascular disease in patients with depression ( 11 , 12 ). Moreover, autonomic dysfunction seems to be associated with cognitive impairment as reported by Forte et al. in their systematic review, which is part of this article collection. In 20 studies comprising data from 19, 431 study participants, they found that both increased sympathetic activity and decreased parasympathetic activity are associated with cognitive impairment. Notably, in the majority of included studies these associations were independent from demographic and clinical characteristics supporting a direct link between impairment of autonomic and cognitive functional integrity. Viewed in conjunction with the complex etiopathogenesis of autonomic dysfunction these observations highlight the need for personalized diagnostic and therapeutic strategies for disorders of the autonomic nervous system. Possible keys to improve early detection and personalized treatment of autonomic dysfunction comprise interdisciplinary symptom-driven clinical management strategies, advancement of assessment and further elucidation of the pathophysiological pathways leading to dysautonomia. Thus, interdisciplinary research on the autonomic nervous system has the potential to help improve quality of life, reduce mortality, and improve cardiovascular health. This would have implications for diseases that extend far beyond classic autonomic disorders such as diabetic neuropathy. Our article collection aims to provide a platform to foster autonomic neuroscience.

Author Contributions

TS drafted the first version of the manuscript. BM-W and KB revised the manuscript for intellectual content.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

In our capacity as guest editors we would like to express our sincere appreciation to the authors of this Research Topic.

References

1. Morgan J. Phillip Low: the autonomic expert. Lancet Neurol.(2018) 17: 743. doi: 10. 1016/S1474-4422(17)30287-9

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Freeman R. Autonomic peripheral neuropathy. Lancet.(2005) 365: 1259–70. doi: 10. 1016/s0140-6736(05)74815-7

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol . (2007) 113: 421–9. doi: 10. 1007/s00401-007-0193-x

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Tsukita K, Sakamaki-Tsukita H, Tanaka K, Suenaga T, Takahashi R. Value of in vivo α-synuclein deposits in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord.(2019) 34: 1452–63. doi: 10. 1002/mds. 27794

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Ziemssen T, Siepmann T. The investigation of the cardiovascular and sudomotor autonomic nervous system-a review. Front Neurol.(2019) 10: 53. doi: 10. 3389/fneur. 2019. 00053

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Low PA. Testing the autonomic nervous system. Semin Neurol . (2003) 23: 407–21. doi: 10. 1055/s-2004-817725

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Siepmann T, Illigens BM, Barlinn K. Alpha-synuclein in cutaneous small nerve fibers. Neuropsychiatr Dis Treat . (2016) 12: 2731–5. doi: 10. 2147/NDT. S117423

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Wang N, Gibbons CH, Lafo J, Freeman R. α-Synuclein in cutaneous autonomic nerves. Neurology.(2013) 81: 1604–10. doi: 10. 1212/WNL. 0b013e3182a9f449

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Doppler K, Ebert S, Üçeyler N, Trenkwalder C, Ebentheuer J, Volkmann J, et al. Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology. Acta Neuropathol.(2014) 128: 99–109. doi: 10. 1007/s00401-014-1284-0

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Zella S. M. A., Metzdorf J, Ciftci E, Ostendorf F, Muhlack S, Gold R, et al. Emerging immunotherapies for Parkinson disease. Neurol Ther . (2019) 8: 29–44. doi: 10. 1007/s40120-018-0122-z

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, et al. Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care.(2010) 33: 1578–84. doi: 10. 2337/dc10-0125

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Fiedorowicz JG. Depression and cardiovascular disease: an update on how course of illness may influence risk. Curr Psychiatry Rep.(2014) 16: 492. doi: 10. 1007/s11920-014-0492-6

PubMed Abstract | CrossRef Full Text | Google Scholar